Disease relevance of Aminothiadiazole

• Effects of 2-amino-1,3,4-thiadiazole on ribonucleotide pools of leukemia L1210 cells [1].
• The effects of 2-amino-1,3,4-thiadiazole [aminothiadiazole (NSC 4728)] on purine and pyrimidine ribonucleotide pools of L1210 ascites cells in vivo are presented and discussed as they relate to the site of action [1].
• High-dose aminothiadiazole in advanced colorectal cancer. An Illinois Cancer Center phase II trial [2].
• One hundred and forty-four evaluable patients with recurrent or metastatic renal cell carcinoma (RCC) were treated with vinblastine infusion (n = 35), L-alanosine (n = 36), acivicin (n = 27), or aminothiadiazole (n = 46) [3].
• Thirty-two evaluable patients with advanced epithelial ovarian cancer were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly [4].

High impact information on Aminothiadiazole

• These results suggest that IMP dehydrogenase is the site of action for aminothiadiazole metabolites as was indicated by earlier observations [5].
• Aminothiadiazole did not inhibit IMP dehydrogenase isolated from L1210 cells [1].
• Studies of 7 beta-[2-(aminoaryl)acetamido]-cephalosporin derivatives. III. Synthesis and structure-activity relationships in the aminothiadiazole series [6].
• The effect of aminothiadiazole on glycogenesis and glycogenolysis in fetal and neonatal rat liver [7].
• At day 15, 16, or 17 of gestation (sperm day = day 0) pregnant Sprague-Dawley rats received a single IP injection of an aqueous solution of aminothiadiazole [7].

Chemical compound and disease context of Aminothiadiazole

• Thirty-three patients with advanced colorectal carcinoma were entered on a phase II trial of weekly IV aminothiadiazole (175 mg/m2 escalated to 200 mg/m2) with concomitant allopurinol and non-steroidal anti-inflammatory agents (NSAID's) [2].

Anatomical context of Aminothiadiazole

• Twenty-one evaluable patients with advanced carcinoma of the endometrium were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly [8].
• Aminothiadiazole in this dose schedule appears to have no utility in previously treated patients with mixed mesodermal tumors of the uterus [9].
• Phase II study of aminothiadiazole in advanced squamous cell carcinoma of the esophagus [10].
• Aminothiadiazole (NSC 4728) in patients with advanced nonsquamous carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group [11].

Analytical, diagnostic and therapeutic context of Aminothiadiazole

• Retention volume of the metabolite on a high-pressure liquid chromatography system is the same as that of the aminothiadiazole mononucleotide prepared as described above [5].
• The Gynecologic Oncology Group chose to study aminothiadiazole in patients with mixed mesodermal tumors of the uterus refractory to prior chemotherapy [9].

References